{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T12:25:16Z","timestamp":1775219116543,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00417-025-06982-8","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:46:38Z","timestamp":1760168798000},"page":"3319-3330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ranibizumab biosimilars vs. reference Ranibizumab for neovascular age-related macular degeneration: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"263","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3329-1014","authenticated-orcid":false,"given":"Nuno","family":"Rodrigues Alves","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patr\u00edcia Barros","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catarina","family":"Bar\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00edvio","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Donato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Bas\u00edlio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Anjos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,11]]},"reference":[{"key":"6982_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(20)30489-7","volume":"9","author":"JD Steinmetz","year":"2021","unstructured":"Steinmetz JD, Bourne RRA, Briant PS et al (2021) Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the right to sight: an analysis for the global burden of disease study. Lancet Glob Health 9:e144\u2013e160. https:\/\/doi.org\/10.1016\/S2214-109X(20)30489-7","journal-title":"Lancet Glob Health"},{"key":"6982_CR2","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2222545","author":"I Korva-Gurung","year":"2023","unstructured":"Korva-Gurung I, Kubin A-M, Ohtonen P, Hautala N (2023) Incidence and prevalence of neovascular age-related macular degeneration: 15-year epidemiological study in a population-based cohort in Finland. Ann Med. https:\/\/doi.org\/10.1080\/07853890.2023.2222545","journal-title":"Ann Med"},{"key":"6982_CR3","unstructured":"WHO (2024) Ageing and health. In: World Health Organization. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/ageing-and-health"},{"key":"6982_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13144227","volume":"13","author":"D \u015apiewak","year":"2024","unstructured":"\u015apiewak D, Drzyzga \u0141, Dorecka M, Wygl\u0119dowska-Promie\u0144ska D (2024) Summary of the therapeutic options for patients with dry and neovascular AMD. J Clin Med 13:4227. https:\/\/doi.org\/10.3390\/jcm13144227","journal-title":"J Clin Med"},{"key":"6982_CR5","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s12325-017-0484-0","volume":"34","author":"A Danyliv","year":"2017","unstructured":"Danyliv A, Glanville J, McCool R (2017) The clinical effectiveness of Ranibizumab treat and extend regimen in nAMD: systematic review and network meta-analysis. Adv Ther 34:611\u2013619. https:\/\/doi.org\/10.1007\/s12325-017-0484-0","journal-title":"Adv Ther"},{"key":"6982_CR6","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.18553\/jmcp.2021.27.9.1260","volume":"27","author":"A Almony","year":"2021","unstructured":"Almony A, Keyloun KR, Shah-Manek B et al (2021) Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis. J Manag Care Spec Pharm 27:1260\u20131272. https:\/\/doi.org\/10.18553\/jmcp.2021.27.9.1260","journal-title":"J Manag Care Spec Pharm"},{"key":"6982_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex278","volume":"56","author":"AG Vulto","year":"2017","unstructured":"Vulto AG, Jaquez OA (2017) The process defines the product: what really matters in biosimilar design and production? Rheumatology 56:iv14\u2013iv29. https:\/\/doi.org\/10.1093\/rheumatology\/kex278","journal-title":"Rheumatology"},{"key":"6982_CR8","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s40123-022-00488-w","volume":"11","author":"SM Hariprasad","year":"2022","unstructured":"Hariprasad SM, Gale RP, Weng CY (2022) An introduction to biosimilars for the treatment of retinal diseases: a narrative review. Ophthalmol Ther 11:959\u2013982. https:\/\/doi.org\/10.1007\/s40123-022-00488-w","journal-title":"Ophthalmol Ther"},{"key":"6982_CR9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41433-022-02246-5","volume":"37","author":"A Sharma","year":"2023","unstructured":"Sharma A, Kondo M, Iwahashi C (2023) Approved biosimilar ranibizumab\u2014a global update. Eye 37:200\u2013202. https:\/\/doi.org\/10.1038\/s41433-022-02246-5","journal-title":"Eye"},{"key":"6982_CR10","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1136\/bjophthalmol-2021-319637","volume":"107","author":"NM Bressler","year":"2023","unstructured":"Bressler NM, Veith M, Hamouz J et al (2023) Biosimilar SB11 versus reference Ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes. Br J Ophthalmol 107:384\u2013391. https:\/\/doi.org\/10.1136\/bjophthalmol-2021-319637","journal-title":"Br J Ophthalmol"},{"key":"6982_CR11","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.oret.2023.05.005","volume-title":"Ophthalmology Retina","author":"A Loewenstein","year":"2023","unstructured":"Loewenstein A, Czumbel N, Ernest J et al (2023) Randomized Trial of Biosimilar XSB-001 versus Reference Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration. Ophthalmology Retina. Elsevier Inc., pp 753\u2013761 https:\/\/doi.org\/10.1016\/j.oret.2023.05.005"},{"key":"6982_CR12","doi-asserted-by":"publisher","unstructured":"Hatamnejad A, Dadak R, Orr S et al (2023) Systematic review of efficacy and meta-analysis of safety of Ranibizumab biosimilars relative to reference Ranibizumab anti-VEGF therapy for nAMD treatment. BMJ Open Ophthalmol 8:e001205 https:\/\/doi.org\/10.1136\/bmjophth-2022-001205","DOI":"10.1136\/bmjophth-2022-001205"},{"key":"6982_CR13","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ n71. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"6982_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","volume":"4","author":"TA Ciulla","year":"2020","unstructured":"Ciulla TA, Hussain RM, Pollack JS, Williams DF (2020) Visual acuity outcomes and anti\u2013vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients. Ophthalmol Retina 4:19\u201330. https:\/\/doi.org\/10.1016\/j.oret.2019.05.017","journal-title":"Ophthalmol Retina"},{"key":"6982_CR15","unstructured":"Higgins JPT (2024) Cochrane handbook for systematic reviews of interventions version 6.5 (updated August 2024). In: Cochrane. Available from www.training.cochrane.org\/handbook. Accessed 23 Dec 2024"},{"key":"6982_CR16","unstructured":"Kondo M, Ogura Y, Takahashi K (2022) A phase III study to evaluate the equivalence in efficacy and safety of SJP-0133 to Lucentis in patients with age-related macular degenerations. Atarashi Ganka. (Journal of the Eye)"},{"key":"6982_CR17","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s40123-024-00883-5","volume":"13","author":"AK Ghosh","year":"2024","unstructured":"Ghosh AK, Nikumbh US, Shukla CK et al (2024) Efficacy, safety and immunogenicity of sun\u2019s Ranibizumab biosimilar in neovascular age-related macular degeneration: a phase 3, double-blind comparative study. Ophthalmol Ther 13:1369\u20131382. https:\/\/doi.org\/10.1007\/s40123-024-00883-5","journal-title":"Ophthalmol Ther"},{"key":"6982_CR18","doi-asserted-by":"publisher","unstructured":"Hamouz J, Nowosielska A, \u015awi\u0119ch-Zubilewicz A et al (2024) Efficacy and safety of Ranibizumab biosimilar QL1205 in neovascular age-related macular degeneration: a phase III randomized trial. Ophthalmol Retina. https:\/\/doi.org\/10.1016\/j.oret.2024.10.001","DOI":"10.1016\/j.oret.2024.10.001"},{"key":"6982_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.04.031","author":"FG Holz","year":"2022","unstructured":"Holz FG, Oleksy P, Ricci F, Elsevier Inc. (2022) Efficacy and safety of biosimilar FYB201 compared with Ranibizumab in neovascular age-related macular degeneration. Ophthalmology. https:\/\/doi.org\/10.1016\/j.ophtha.2021.04.031","journal-title":"Ophthalmology"},{"key":"6982_CR20","doi-asserted-by":"publisher","unstructured":"Yoon CK, Oh J, Bae K et al (2022) Efficacy and safety of a new Ranibizumab biosimilar CKD-701 using a pro re Nata treatment regimen in neovascular age-related macular degeneration: a phase 3 randomized clinical trial. PLoS One 17. https:\/\/doi.org\/10.1371\/journal.pone.0275611","DOI":"10.1371\/journal.pone.0275611"},{"key":"6982_CR21","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.2147\/OPTH.S307746","volume":"15","author":"P Apsangikar","year":"2021","unstructured":"Apsangikar P, Ghadge P, Naik M et al (2021) Randomised, double-blind, comparative clinical study of new Ranibizumab biosimilar in neovascular (wet) age-related macular degeneration. Clin Ophthalmol 15:3087\u20133095. https:\/\/doi.org\/10.2147\/OPTH.S307746","journal-title":"Clin Ophthalmol"},{"key":"6982_CR22","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.4103\/ijo.IJO_2118_21","volume":"70","author":"R Singh","year":"2022","unstructured":"Singh R, Chauhan R, Saxena A et al (2022) A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of lupin\u2019s Ranibizumab with Lucentis \u00ae in patients with neovascular age-related macular degeneration. Indian J Ophthalmol 70:3008\u20133014. https:\/\/doi.org\/10.4103\/ijo.IJO_2118_21","journal-title":"Indian J Ophthalmol"},{"key":"6982_CR23","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.2147\/OPTH.S488866","volume":"18","author":"PJ Rana","year":"2024","unstructured":"Rana PJ, Deshmukh H, Shah U et al (2024) Efficacy and safety of biosimilar Ranibizumab (OPTIMAB\u00ae) versus innovator Ranibizumab in patients with neovascular (wet) age-related macular degeneration: a double-blind, randomized, multicenter, phase III study. Clin Ophthalmol 18:3071\u20133081. https:\/\/doi.org\/10.2147\/OPTH.S488866","journal-title":"Clin Ophthalmol"},{"key":"6982_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jamaophthalmol.2020.5053","volume":"139","author":"SJ Woo","year":"2021","unstructured":"Woo SJ, Veith M, Hamouz J et al (2021) Efficacy and safety of a proposed Ranibizumab biosimilar product vs a reference Ranibizumab product for patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmol 139:68\u201376. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.5053","journal-title":"JAMA Ophthalmol"},{"key":"6982_CR25","unstructured":"ClinicalTrials.gov identifier: NCT04690556 A global, phase III double blind, randomized controlled study to compare the efficacy, safety & immunogenicity of LUBT010 with Lucentis\u00ae in patients with neovascular age related macular degeneration. https:\/\/clinicaltrials.gov\/study\/NCT04690556?term=NCT04690556&rank=1"},{"issue":"4","key":"6982_CR26","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.ophtha.2009.09.002","volume":"117","author":"NM Bressler","year":"2010","unstructured":"Bressler NM, Chang TS, Su\u00f1er IJ (2010) Vision-related function after Ranibizumab treatment by better- or worse-seeing eye. Ophthalmology 117(4):747-756e4. https:\/\/doi.org\/10.1016\/j.ophtha.2009.09.002","journal-title":"Ophthalmology"},{"key":"6982_CR27","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1097\/IAE.0000000000003194","volume":"41","author":"PK Kaiser","year":"2021","unstructured":"Kaiser PK, Wykoff CC, Singh RP (2021) Retinal fluid and thickness as measures of disease activity in neovascular age-related macular degeneration. Retina 41:1579\u20131586. https:\/\/doi.org\/10.1097\/IAE.0000000000003194","journal-title":"Retina"},{"key":"6982_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","volume":"148","author":"GA Lalwani","year":"2009","unstructured":"Lalwani GA, Rosenfeld PJ, Fung AE et al (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the pronto study. Am J Ophthalmol 148:43-58e1. https:\/\/doi.org\/10.1016\/j.ajo.2009.01.024","journal-title":"Am J Ophthalmol"},{"key":"6982_CR29","unstructured":"U.S. Department of Health and Human Services C for DE and RC for BE and Research (2015) Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry"},{"key":"6982_CR30","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (2014) Guideline on similar biological medicinal products"},{"key":"6982_CR31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1136\/bjophthalmol-2019-314443","volume":"104","author":"A Sharma","year":"2020","unstructured":"Sharma A, Kumar N, Kuppermann BD et al (2020) Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective. Br J Ophthalmol 104:2\u20137. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-314443","journal-title":"Br J Ophthalmol"},{"key":"6982_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000900","volume":"5","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Goncalves J, Quinn M (2019) Era of biosimilars in rheumatology: reshaping the healthcare environment. RMD Open 5:e000900. https:\/\/doi.org\/10.1136\/rmdopen-2019-000900","journal-title":"RMD Open"},{"key":"6982_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000502747","volume":"243","author":"J Mon\u00e9s","year":"2020","unstructured":"Mon\u00e9s J, Singh RP, Bandello F et al (2020) Undertreatment of neovascular age-related macular degeneration after 10 years of anti-vascular endothelial growth factor therapy in the real world: the need for a change of mindset. Ophthalmologica 243:1\u20138. https:\/\/doi.org\/10.1159\/000502747","journal-title":"Ophthalmologica"},{"key":"6982_CR34","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/eye.2015.217","volume":"30","author":"V Chong","year":"2016","unstructured":"Chong V (2016) Ranibizumab for the treatment of wet AMD: a summary of real-world studies. Eye 30:270\u2013286. https:\/\/doi.org\/10.1038\/eye.2015.217","journal-title":"Eye"},{"key":"6982_CR35","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","volume":"99","author":"FG Holz","year":"2015","unstructured":"Holz FG, Tadayoni R, Beatty S et al (2015) Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 99:220\u2013226. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305327","journal-title":"Br J Ophthalmol"},{"key":"6982_CR36","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1097\/IAE.0000000000002670","volume":"40","author":"FG Holz","year":"2020","unstructured":"Holz FG, Figueroa MS, Bandello F et al (2020) RANIBIZUMAB TREATMENT IN TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina 40:1673\u20131685. https:\/\/doi.org\/10.1097\/IAE.0000000000002670","journal-title":"Retina"},{"key":"6982_CR37","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/imj.14787","volume":"50","author":"PC Robinson","year":"2020","unstructured":"Robinson PC, Conrad D (2020) Biologic therapy for uveitis: addressing access issues is paramount. Intern Med J 50:508\u2013509. https:\/\/doi.org\/10.1111\/imj.14787","journal-title":"Intern Med J"},{"key":"6982_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015804.pub2","author":"T Sunaga","year":"2024","unstructured":"Sunaga T, Maeda M, Saulle R et al (2024) Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration. Cochrane Database Syst Reviews 2024. https:\/\/doi.org\/10.1002\/14651858.CD015804.pub2","journal-title":"Cochrane Database Syst Reviews 2024"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06982-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-025-06982-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06982-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T14:39:55Z","timestamp":1770647995000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-025-06982-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,11]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["6982"],"URL":"https:\/\/doi.org\/10.1007\/s00417-025-06982-8","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,11]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required, as this study is a systematic review and meta-analysis based on previously published data. The study was conducted in accordance with the PRISMA guidelines and was prospectively registered in PROSPERO.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was not required for this study, as it involved secondary analysis of data from previously published studies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}